search
Back to results

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Primary Purpose

Prader-Willi Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
NNZ-2591
Sponsored by
Neuren Pharmaceuticals Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prader-Willi Syndrome focused on measuring Prader-Willi Syndrome

Eligibility Criteria

4 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of PWS with a documented disease-causing genetic abnormality of the chromosome 15q11-q13 confirmed by DNA methylation and microarray. Males or females aged 4-12 years, inclusive. Body weight of 12 kg to 100kg (inclusive) at Baseline. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at the Screening visit. Must currently be on treatment with growth hormone. Each subject must be able to swallow the study medication provided as a liquid solution. Caregiver(s) must have sufficient English language skills. Subject and caregiver must reside in the US and have been resident in the US for at least 3 months prior to screening. Exclusion Criteria: Body weight <12 kg or >100 kg at Baseline. HbA1c values above 7% at the Screening visit. Clinically significant abnormalities in safety laboratory tests and vital signs at Screening. Positive pregnancy test at the Screening visit. Positive drugs of abuse screen not explained by concomitant medications. Abnormal QTcF interval or prolongation at Screening. Any other clinically significant finding on ECG at the Screening visit. Positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or Baseline. Previous COVID 19 infection with last 12 months that required hospitalization. Previous COVD-19 infection involving multi-organ systems, resulting in Multisystem Inflammatory Syndrome in Children (MIS-C) or with clinically significant long term effects. COVID-19 infection associated with acute kidney injury (AKI) or renal conditions. Renal conditions or abnormalities identified in laboratory testing, imaging or medical history. Liver conditions and Hepatic abnormalities. Vision abnormalities and Ocular conditions. Excluded concomitant treatments. Unstable seizure profile. Current clinically significant cardiovascular, gastrointestinal, or respiratory disease, or clinically significant organ impairment, or endocrine disease with the exception of obesity and controlled hypothyroidism. Current clinically significant hypo or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes. Has planned surgery during the study. History of, or current, cerebrovascular disease or brain trauma. History of, or current catatonia or catatonia-like symptoms. History of, or current, malignancy. Current major or persistent depressive disorder (including bipolar depression). Significant uncorrected hearing impairment. Allergy to strawberry. Has participated in another interventional clinical study within 30 days prior to start of Screening. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study.

Sites / Locations

  • Rare Disease ResearchRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NNZ-2591

Arm Description

NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Outcomes

Primary Outcome Measures

Safety and Tolerability
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Pharmacokinetic - Measurement of Cmax
Maximum observed concentration (Cmax) of NNZ-2591
Pharmacokinetic - Measurement of AUC
Area under the concentration-time curve of NNZ-2591
Pharmacokinetic - Measurement of time to Cmax
Time to Cmax of NNZ-2591
Pharmacokinetic - Measurement of t1/2
Apparent terminal elimination half-life of NNZ-2591

Secondary Outcome Measures

Exploratory efficacy measurement
Assessed by PWS-specific Clinical Global Impression Scale & Domain -Overall Improvement Score (CGI-I)
Exploratory efficacy measurement
Assessed by Caregiver Global Impression-Change Score
Exploratory efficacy measurement
Assessed by PWS-specific Clinical Global Impression Scale-Severity (CGI-S) Overall Score
Exploratory efficacy measurement
Assessed by Caregiver Top 3 Concerns Likert Scale Scores
Exploratory efficacy measurement
Assessed by PWS Profile Score
Exploratory efficacy measurement
Assessed by PWS Anxiousness and Distress Behaviors Questionnaire Score (PADQ)
Exploratory efficacy measurement
Assessed by Autism Diagnostic Observation Schedule (ADOS-2), Repetitive behaviors and Social scores
Exploratory efficacy measurement
Assessed by Hyperphagia Questionnaire-Clinical Trials (HQ-CT) Score
Exploratory efficacy measurement
Assessed by Food Safety Zone Questionnaire Score
Exploratory efficacy measurement
Assessed by Vineland Adaptive Behavior Scales-3 Growth Scale Scores
Exploratory efficacy measurement
Assessed by Zarit Burden Interview Score
Exploratory efficacy measurement
Assessed by Child Sleep Habits Questionnaire (CSHQ)
Exploratory efficacy measurement
Assessed by Impact of Childhood Neurological Disability Scale (ICND)
Exploratory efficacy measurement
Assessed by Quality of Life Inventory-Disability (QI-Disability)
Exploratory efficacy measurement
Assessed by Kaufman Brief Intelligence Test or Mullen Scales of Early Learning
Exploratory efficacy measurement
Assessed by PWS Suicidality Assessment
Exploratory efficacy measurement
Assessed by Caregiver Diary

Full Information

First Posted
May 18, 2023
Last Updated
September 1, 2023
Sponsor
Neuren Pharmaceuticals Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05879614
Brief Title
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Acronym
PWS-001
Official Title
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2023 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neuren Pharmaceuticals Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.
Detailed Description
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Prader-Willi Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prader-Willi Syndrome
Keywords
Prader-Willi Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NNZ-2591
Arm Type
Experimental
Arm Description
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Intervention Type
Drug
Intervention Name(s)
NNZ-2591
Other Intervention Name(s)
Cyclo-L-Glycyl-L-2-Allylproline
Intervention Description
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Primary Outcome Measure Information:
Title
Safety and Tolerability
Description
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of Cmax
Description
Maximum observed concentration (Cmax) of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of AUC
Description
Area under the concentration-time curve of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of time to Cmax
Description
Time to Cmax of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of t1/2
Description
Apparent terminal elimination half-life of NNZ-2591
Time Frame
13 weeks
Secondary Outcome Measure Information:
Title
Exploratory efficacy measurement
Description
Assessed by PWS-specific Clinical Global Impression Scale & Domain -Overall Improvement Score (CGI-I)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Caregiver Global Impression-Change Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by PWS-specific Clinical Global Impression Scale-Severity (CGI-S) Overall Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Caregiver Top 3 Concerns Likert Scale Scores
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by PWS Profile Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by PWS Anxiousness and Distress Behaviors Questionnaire Score (PADQ)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Autism Diagnostic Observation Schedule (ADOS-2), Repetitive behaviors and Social scores
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Hyperphagia Questionnaire-Clinical Trials (HQ-CT) Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Food Safety Zone Questionnaire Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Vineland Adaptive Behavior Scales-3 Growth Scale Scores
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Zarit Burden Interview Score
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Child Sleep Habits Questionnaire (CSHQ)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Impact of Childhood Neurological Disability Scale (ICND)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Quality of Life Inventory-Disability (QI-Disability)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Kaufman Brief Intelligence Test or Mullen Scales of Early Learning
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by PWS Suicidality Assessment
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Caregiver Diary
Time Frame
13 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of PWS with a documented disease-causing genetic abnormality of the chromosome 15q11-q13 confirmed by DNA methylation and microarray. Males or females aged 4-12 years, inclusive. Body weight of 12 kg to 100kg (inclusive) at Baseline. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at the Screening visit. Must currently be on treatment with growth hormone. Each subject must be able to swallow the study medication provided as a liquid solution. Caregiver(s) must have sufficient English language skills. Subject and caregiver must reside in the US and have been resident in the US for at least 3 months prior to screening. Exclusion Criteria: Body weight <12 kg or >100 kg at Baseline. HbA1c values above 7% at the Screening visit. Clinically significant abnormalities in safety laboratory tests and vital signs at Screening. Positive pregnancy test at the Screening visit. Positive drugs of abuse screen not explained by concomitant medications. Abnormal QTcF interval or prolongation at Screening. Any other clinically significant finding on ECG at the Screening visit. Positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or Baseline. Previous COVID 19 infection with last 12 months that required hospitalization. Previous COVD-19 infection involving multi-organ systems, resulting in Multisystem Inflammatory Syndrome in Children (MIS-C) or with clinically significant long term effects. COVID-19 infection associated with acute kidney injury (AKI) or renal conditions. Renal conditions or abnormalities identified in laboratory testing, imaging or medical history. Liver conditions and Hepatic abnormalities. Vision abnormalities and Ocular conditions. Excluded concomitant treatments. Unstable seizure profile. Current clinically significant cardiovascular, gastrointestinal, or respiratory disease, or clinically significant organ impairment, or endocrine disease with the exception of obesity and controlled hypothyroidism. Current clinically significant hypo or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes. Has planned surgery during the study. History of, or current, cerebrovascular disease or brain trauma. History of, or current catatonia or catatonia-like symptoms. History of, or current, malignancy. Current major or persistent depressive disorder (including bipolar depression). Significant uncorrected hearing impairment. Allergy to strawberry. Has participated in another interventional clinical study within 30 days prior to start of Screening. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
James Shaw
Phone
+61 427 299 669
Email
jshaw@neurenpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Shaw
Organizational Affiliation
Neuren Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Rare Disease Research
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
678-883-6897
Email
subjectrecruiting@rarediseaseresearch.com
First Name & Middle Initial & Last Name & Degree
Han C Phan, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

We'll reach out to this number within 24 hrs